Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis

Accessed on 18 Jun 2012 from http://www.marketwatch.com/story/teva-announces-top-line-results-from-gala-phase-iii-trial-evaluating-a-new-dosage-for-glatiramer-acetate-given-three-times-weekly-for-relapsing-remitting-multiple-sclerosis-2012-06-14.